ArticleNPJ precision oncology2025
Clinical characteristics and predictive models of HER2-low breast cancer patients who only received adjuvant chemotherapy: a real-world retrospective multicenter study.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human Epidermal Growth Factor Receptor 2 Negative, Low, and Overexpression in Breast Cancer Patients: Study on Recurrence-Free and Overall Survival.World journal of oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
HER2-low positivity is reported to play substantial role in neoadjuvant chemotherapy for breast cancer, but its role in adjuvant chemotherapy remains unclear. We aim to explore the role of HER2-low positivity in the breast cancer patients who only received adjuvant chemotherapy. We evaluated 3214 patients from SRRSH Hospital and 16,273 patients from CHLP Hospital. All the patients were diagnosed as primary breast cancer who only received adjuvant chemotherapy. HER2-status was defined according to ASCO/CAP guidelines. Multivariable Cox models and machine learning models were applied in the analysis of overall survival. A total of 1009 HER2-zero, 1399 HER2-low and 806 HER2-positive patients were included in SRRSH cohort, while there were 5662 HER2-zero, 6471 HER2-low and 4140 HER2-positive patients in CHLP cohort. HER2-low patients showed significant better OS and reduced death risk compare to HER2-zero patients in both SRRSH (log-rank p = 0.033, HR = 0.62, 95% CI 0.39-0.97, p = 0.037) and CHLP cohort (log-rank p < 0.001, HR = 0.63, 95% CI 0.55-0.73, p < 0.001). In subgroup analysis, HER2-low patients had significantly reduced risk of death compare to HER2-zero patients in hormonal receptor-positive subset in both cohorts, but not in hormonal receptor-negative subset. MLP model demonstrated the best performance among all the predictive models in both cohorts. Our study indicated that HER2-low patients had better survival compare to HER2-zero patients in adjuvant chemotherapy only setting. We emphasized the significance of HER2 status in adjuvant setting in BC, implying more precise diagnostic and therapeutic strategies in future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.